A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non–Small-cell Lung Cancer: The OPAL Study …
H Asahina, K Tanaka, S Morita, M Maemondo… - Clinical Lung Cancer, 2021 - Elsevier
Background Osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, is now a standard treatment of previously untreated EGFR-mutated …
tyrosine kinase inhibitor, is now a standard treatment of previously untreated EGFR-mutated …
A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study …
H Asahina, K Tanaka, S Morita, M Maemondo… - Clinical Lung …, 2020 - europepmc.org
Background Osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, is now a standard treatment of previously untreated EGFR-mutated …
tyrosine kinase inhibitor, is now a standard treatment of previously untreated EGFR-mutated …
A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non–Small-cell Lung Cancer: The OPAL Study …
H Asahina, K Tanaka, S Morita… - Clinical Lung …, 2021 - clinical-lung-cancer.com
Background Osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, is now a standard treatment of previously untreated EGFR-mutated …
tyrosine kinase inhibitor, is now a standard treatment of previously untreated EGFR-mutated …
A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study …
H Asahina, K Tanaka, S Morita… - Clinical lung …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, is now a standard treatment of previously untreated EGFR-mutated …
tyrosine kinase inhibitor, is now a standard treatment of previously untreated EGFR-mutated …
[引用][C] A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non–Small-cell Lung Cancer: The OPAL …
H Asahina, K Tanaka, S Morita, M Maemondo… - Clinical Lung …, 2021 - cir.nii.ac.jp
A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With
EGFR-Mutated Advanced Non–Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801) …
EGFR-Mutated Advanced Non–Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801) …
A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non–Small-cell Lung Cancer: The OPAL Study …
H Asahina, K Tanaka, S Morita… - Clinical Lung …, 2021 - kyushu-u.elsevierpure.com
Background: Osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, is now a standard treatment of previously untreated EGFR-mutated …
tyrosine kinase inhibitor, is now a standard treatment of previously untreated EGFR-mutated …